ACNE THERAPEUTICS MARKET ANALYSIS

Acne Therapeutics MarketSize and Trends

The global acne therapeutics market was valued at US$ 6,342.5 Mn in 2022 and is forecast to reach a value of US$ 8,834.9 Mn by 2030 at a CAGR of 4.2% between 2023 and 2030. The global acne therapeutics market is experiencing strong growth due to the growing prevalence of acne and high demand for safe and effective acne therapeutics. Moreover, increasing research and development and growing awareness among people about available treatment options is expected to propel the growth of the market. However, factors such as high demand for generic drugs and safety issues regarding acne products are expected to hamper the market growth.

Global Acne Therapeutics Market: Regional Insights

Based on geography, the global acne therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Figure 1. Global Acne Therapeutics Market Share (%), by Region, 2023

Global Acne Therapeutics Market Trends:

High demand for creams and gels is a recent trend

Retinoid creams and gels are very effective at stopping or reducing mild to moderate acne, which led to an increasing demand for retinoids. For instance, in February 2022, Stryke Club announced the launch of retinoid acne treatment with its Knockout Adapalene Gel that helps prevent pimples, blackheads, whiteheads, and clogged pores. The rising product launches of retinoid treatment will lead to increasing adoption of the same owing to its benefits, and this trend is expected to continue over the forecast period, driving the market growth.

Introduction of novel drugs is another trend

With the growing burden of acne, the demand for acne therapeutics is also increasing. As a result, players in the market are focusing on developing and launching novel therapeutics in the market. In November 2021, Sun Pharmaceuticals announced the launch of Winlevi (Clascoterone cream 1%), the first-in-class topical therapy for acne vulgaris, in the United States. WINLEVI is approved by FDA for the topical treatment of acne vulgaris in patients 12 years of age and older. This trend is also expected to continue over the forecast period.